Lineage Cell Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Lineage Cell's Property Plant And Equipment Net is fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 75.6 M in 2025, despite the fact that Net Debt is likely to grow to (27.8 M). Key indicators impacting Lineage Cell's financial strength include:
The financial analysis of Lineage Cell is a critical element in measuring its lifeblood. Investors should not minimize Lineage Cell's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the imprecision that can be found in Lineage Cell's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lineage Cell Therapeutics. Check Lineage Cell's Beneish M Score to see the likelihood of Lineage Cell's management manipulating its earnings.
Lineage Cell Stock Summary
Lineage Cell competes with MAIA Biotechnology, Armata Pharmaceuticals, Portage Biotech, Cadrenal Therapeutics,, and ImmuCell. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Lineage Cell operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 57 people.
Foreign Associate
Israel
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of Lineage Cell Therapeutics. It measures of how well Lineage is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Lineage Cell brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Lineage had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Lineage Cell has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Lineage Cell's current stock value. Our valuation model uses many indicators to compare Lineage Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lineage Cell competition to find correlations between indicators driving Lineage Cell's intrinsic value. More Info.
Lineage Cell Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Lineage Cell's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lineage Cell's earnings, one of the primary drivers of an investment's value.
Lineage Cell Therapeutics Systematic Risk
Lineage Cell's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lineage Cell volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Lineage Cell Therapeutics correlated with the market. If Beta is less than 0 Lineage Cell generally moves in the opposite direction as compared to the market. If Lineage Cell Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lineage Cell Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lineage Cell is generally in the same direction as the market. If Beta > 1 Lineage Cell moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Lineage Cell Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lineage Cell's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lineage Cell growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Lineage Cell help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lineage Cell Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lineage Cell Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Lineage Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lineage Cell's daily price indicators and compare them against related drivers.
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.